Global Cough Suppressant Drugs Market, By Type (Acute Cough, Chronic Cough), Drugs (Dextromethorphan, Codeine, Butramirate, Bennzonatate, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cough Suppressant Drugs Market Analysis and Size
The global cough suppressant drugs market is expected to witness significant growth during the forecast period. Introducing new cough suppressants in the market by major market layers is definitely saving a lot of patients lives. Medical advancements which involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market growth. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cough suppressant drugs market in the forecast period 2022-2029. The expected CAGR of global cough suppressant drugs market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 1.33 billion in 2021, and it would grow upto USD 1.89 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Cough suppressant drugs are also known as antitussives agent that suppresses coughing. These drugs utilize their effect by hindering cough centres located in the brain stem. Cough suppressant reduces the activity of cough reflex and suppresses the urge to cough. The most common cough suppressans widely used are Dextromethorphan and Codeine. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Cough Suppressant Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute Cough, Chronic Cough), Drugs (Dextromethorphan, Codeine, Butramirate, Bennzonatate, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Biocon (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Amneal Pharmaceuticals LLC. (U.K.), Glenmark Pharmaceuticals Inc (India)
|
|
Market Opportunities
|
|
Global Cough Suppressant Drugs Market Dynamics
Drivers
- Increased Initiatives by Government and Market Players
The increasing number of efforts and initiatives that are being initiated by the government and major market leaders all over the world are boosting the market growth. Governments in many countries have launched several initiatives towards launching more and more drugs for chronic cough that will help in the betterment of the patients. Thus, these factors drive the market growth.
- Higher Approvals and Launch of New Drugs
The launches of several drugs and its subsequent approvals are boosting the growth of the market. For instance, In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength. This is indicated to control coughs and to break up mucus. It is recommended to be taken 1200 mg/60 mg. Approval and launch of such new drugs are expected to drive the cough suppressant drugs market growth during the forecast period.
Opportunities
- Increased Prevalence of Cough
According to the reports of CDC, around 25 million people had asthma in the U.S. in 2017, and it is commonly diagnosed among adult women than in men. The organization also stated that incidence of asthma was 7.8% in 2015, which rise upto 7.9% in 2017, in North America. This creates more opportunity in the market.
- Strategic Partnerships and Collaborations
Major market players are involved in strategic mergers and partnerships to develop, manufacture, and sell cough suppressant drugs and gain major market share. For instance, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare, in 2015. According to the agreement, Pfizer Consumer Healthcare will commercialize dextromethorphan cough syrup under the Robitussin Brand. In return, Tris will provide the U.S. branded rights to its protected intellectual property for a prolonged dextromethorphan formulation to Pfizer Consumer Healthcare. Consequently, Tris will receive an upfront payment, milestone payments, and sales-based payment royalties.
Restraints/Challenges
- Less Trained Professionals
Less trained individuals who are unable to handle the cough patients are acting as a restrain to the market growth. Many times, the disease might get complicated and the professionals may not understand the underlying cause of the disease. Hence, it acts negatively to the patients and as a result hampers the market growth.
- Side effects of cough suppressants
Various side effects associated with cough suppressant drugs such as drowsiness, dizziness, constipation, stomach upset, blurred vision, or dry mouth/nose/throat are likely to hinder the market growth in the forecast period of 2022 to 2029.
This global cough suppressant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cough suppressant drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Cough Suppressant Drugs Market
COVID-19 left a major impact on the global cough suppressant drugs market. Cough remedies can be used to manage cough caused as a symptom after COVID-19 exposure. Nevertheless, workforce shortages and resource limitations, because of COVID-19, are expected to negatively impact the industry's growth in the forecast period. There has been an abrupt growth in R&D activities to bring new products to cure cough which is expected to expand the growth of chronic cough market during the forecast period.
Global Cough Suppressant Drugs Market Scope
The global cough suppressant drugs market is segmented on the basis of type, drugs, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute Cough
- Chronic Cough
Drugs
- Dextromethorphan
- Codeine
- Butramirate,
- Bennzonatate
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cough Suppressant Drugs Market Regional Analysis/Insights
The global cough suppressant drugs market is analysed and market size insights and trends are provided by type, drugs, distribution channel and end-user as referenced above.
The major countries covered in the global cough suppressant drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increasing prevalence of respiratory disorders and occurrence of sophisticated healthcare infrastructure that can result in effective treatment to patient suffering from the cough suppressant drugs.
Asia Pacific dominates the market due to surge population and increase in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cough Suppressant Drugs Market Share Analysis
The global cough suppressant drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cough suppressant drugs market .
Key players operating in the global cough suppressant drugs market include:
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Biocon (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Amneal Pharmaceuticals LLC. (U.K.)
- Glenmark Pharmaceuticals Inc (India)
SKU-